UK – Tagrisso hit with NICE rejection for NSCLC

The National Institute for Health and Care Excellence (NICE) has published a final guidance that does not recommend AstraZeneca’s Tagrisso (osimertinib) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC).

The organisation revealed that the decision was based on a clinical trial, which despite showing that the drug stalled cancer-growth for around 18.9 months compared with 10.2 months in patients treated with erlotinib or gefitinib, did not show direct evidence that the drug would be more effective than afatinib, which may be more effective than erlotinib or gefitinib.

As it stands, the first line of treatment for locally advanced stages of NSCLC is a daily oral dose of afatinib, erlotinib, gefitinib or dacomitinib, which have all previously been recommended by NICE…